Excelsior Sciences raises $95 million for drug discovery with AI-ready chemistry
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
Here's a development that aims to keep your blood pressure in check. Literally!
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
Suffering from acute migraine? You may soon bid adieu to the debilitating headache
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
Subscribe To Our Newsletter & Stay Updated